Media stories about Oasmia Pharmaceutical (NASDAQ:OASM) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oasmia Pharmaceutical earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.3688145194985 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Oasmia Pharmaceutical (OASM) traded up $0.02 during trading hours on Tuesday, hitting $0.97. The company had a trading volume of 800 shares, compared to its average volume of 12,465. Oasmia Pharmaceutical has a fifty-two week low of $0.80 and a fifty-two week high of $3.70.
COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/05/favorable-media-coverage-somewhat-unlikely-to-affect-oasmia-pharmaceutical-oasm-share-price.html.
About Oasmia Pharmaceutical
Oasmia Pharmaceutical AB (publ) develops, produces, markets, and sells drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The companys approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer.
Receive News & Ratings for Oasmia Pharmaceutical AB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB and related companies with MarketBeat.com's FREE daily email newsletter.